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http:WHAT THIS PAPER ADDS
This is the ﬁrst nationwide study that investigates the relationship between the timing of intervention (CAS)
after onset of neurologic events, and peri-operative complications. Our data support previous data that CAS
within 1 week does not confer an increased risk. Therefore, in patients who are neurologically stable and have an
indication for intervention, CAS should not be delayed.Objectives: Current European Society for Vascular Surgery guidelines recommend that patients with a
symptomatic carotid stenosis should be operated on within 14 days of onset of symptoms. Recent reports
indicate that carotid endarterectomy (CEA) within 2 days of a neurological event may be associated with a higher
peri-procedural risk of stroke. Whether urgent carotid artery stenting (CAS) carries a similar high risk is unclear.
The aim of this study was to analyze if urgent CAS increases the peri-procedural risks.
Methods: Retrospective analysis of all CAS registered in Swedvasc, a validated nationwide registry, between
January 1, 2005, and March 20, 2014. Only symptomatic patients treated for a stenosis of the internal carotid
artery were included. Patients were categorized according to time from index event to surgery; 0e2 days, 3e7
days, 8e14 days, and 15e180 days. Primary outcome was 30 day combined stroke and death rate.
Results: 323 patients underwent CAS for symptomatic carotid artery stenosis. The demographic and clinical data
were similar in the groups. No procedure related complications or deaths were observed in the urgent CAS
group. The 30 day combined stroke and death rate did not differ signiﬁcantly between the groups; zero of 13 (0%;
95% CI 0e26.6) in the group treated 0e2 days versus four of 85 (4.7%; 95% CI 1.5e11.9), at 3e7 days, ﬁve of 80
(6.3%; 95% CI 2.4e14.1) at 8e14 days, and six of 145 (4.1%; 95% CI 1.7e8.9) for the patients treated at 15e180
days (p ¼ .757). Stroke and death were not more frequent for patients treated within 1 week compared with
after 1 week: 4 out of 98 (4.1%; 95% CI 1.3e9.0) versus 11/225 (4.9%; 95% CI 2.7e8.6) (p ¼ .751).
Conclusions: In this national registry study, CAS performed within 1 week of the onset of a neurologic event was
not associated with an additional risk of a peri-operative complication compared with those treated
subsequently.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Transient ischemic attackINTRODUCTION
The risk of recurrent stroke after a transient ischemic attack
(TIA) or a minor stroke is very high early after the ﬁrst
incident, up to 10% the ﬁrst week.1e4 The majority of all
strokes that occur within 30 days of a TIA occur within the
ﬁrst 48 hours of the index event.5e8 Data from ECST and
NASCET showed that for patients with a symptomaticresponding author. M. Jonsson, Section of Vascular surgery,
ment of Surgery, Södersjukhuset, 118 83 Stockholm, Sweden.
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//dx.doi.org/10.1016/j.ejvs.2015.01.007carotid stenosis, carotid endarterectomy (CEA) is most
beneﬁcial when performed within the ﬁrst 2 weeks,9,10 and
current guidelines recommend revascularization within the
ﬁrst 2 weeks of the qualifying event.11e13
Although the literature is disparate, some recent reports
have questioned the beneﬁt of very early CEA due to a po-
tential risk of increased peri-operative complications.14e18
Whether urgent carotid artery stenting (CAS) carries a high
risk is unclear.
There is evidence from randomized trials of an increased
risk with CAS compared with CEA.19e21 Thus, CAS could be
even more questionable in the acute period since an un-
stable plaque increases the risk of embolization during
Peri-procedural Risk with Urgent Carotid Artery Stenting 507passage of the wire, protection device, or stent across the
lesion. Magnetic resonance imaging data from the ICSS
study showed a three times higher incidence of new
ischemic lesions after CAS than CEA.22 Soft, lipid rich pla-
que, pre-occlusive lesion, and plaque ulceration increase
the peri-procedural stroke risk for CAS.23,24 However, the
possible increased risk of intervention must be counter-
balanced against the risk of recurrent stroke in this acute
phase. Studies that report risks with urgent CAS are few and
include a limited number of patients.25e30
The aim of this retrospective nationwide cohort study
was to determine the procedural risk of CAS for symp-
tomatic carotid stenosis in relation to the time from the
qualifying neurological event.
MATERIALS AND METHODS
Study design
A retrospective nationwide cohort study of all patients in
the National Swedish Registry of Vascular Surgery (Swed-
vasc) treated by CAS between January 1, 2005, and March
20, 2014. The regional ethics committee in Stockholm
approved the study (No 2013/2191).Swedvasc data
The Swedvasc registry has had national coverage since 1994
(version 1.0), and includes all centers performing CEA and/or
CAS in the country. Procedure data are recorded along with
basic demographics and risk factors. The follow up protocol
includes clinical examination and registration of peri-operative
complications at 30 days. Mortality data are retrieved directly
from the Swedish National Population Registry and are
updated monthly. Causes of death are not included in the
Registry. BeforeMay 2008 the parameter “heart risk” included
atrial ﬁbrillation in Swedvasc but not thereafter.
Cases with incomplete Swedvasc data for date of quali-
fying event or outcome data have been completed by
retrieving charts from the hospital that carried out the
operation and/or was responsible for the follow up to reach
100% follow up.
The external validity of Swedvasc is high. For example,
the external validity for carotid surgery is 93.6% compared
with the Swedish Hospital Discharge Register (SHDR), and
mortality data from the population registry are 100% ac-
curate.31 Data on reason for not performing CEA, use of
statins and antiplatelet drugs post-operatively, degree of
ipsilateral and contralateral stenosis, and protection devices
used were retrieved from patient charts.
The study period covered 9 years (2005e2014). To
explore whether the strategies for treating symptomatic
carotid stenosis had changed during that time, the period
was divided into two parts: January 2005 to August 2009,
and August 2009 to March 2014.Study population
Only procedures for internal carotid artery stenosis were
included in this report. Interventions solely to the commoncarotid were excluded, as were indications other than ICA
stenoses (dissections, aneurysms, and trauma). Only bare
metal stenting was included in the analyses, and covered
stent grafts and percutaneous transluminal angioplasty (PTA)
alone were excluded. CAS cases performed with synchronous
intracranial or aortic arch interventions were also excluded.
Patients operated on bilaterally were identiﬁed, and if they
were more than 30 days apart both operations were recor-
ded separately and included in the analysis.
Deﬁnitions
A symptomatic stenosis was deﬁned as all ipsilateral carotid
artery events within 180 days prior to the intervention. Non-
hemispheric symptoms and ipsilateral carotid artery events
>180 days were excluded. The qualifying event is the
neurological event for which the patient received medical
advice in the healthcare system. The qualifying events were
categorized into TIA, amaurosis fugax, crescendo TIA, minor
and major stroke. The Registry (for the time period studied)
only includes data on minor or major stroke, so a valid re-
classiﬁcation into the Rankin scale is not possible. Time to
intervention was deﬁned as the number of days from the
qualifying event to the day of intervention (0e180 days).
Deﬁnitions included: renal insufﬁciency with creatinine
>150 mmol/L; hypertension on medication or a diastolic
blood pressure of110mmHg; diabetes treatedwith insulin,
oral medication or diet; and smoking by current smoker
(including quit within the last 4 weeks) or non-smoker which
includes ex-smoker and people who have never smoked.
Peri-operative complications included any stroke (ipsi-
lateral, contralateral and vertebrobasilar stroke, including
intracerebral bleeding), acute myocardial infarction (AMI),
and death within 30 days of the procedure. Stroke included
any new or worsened focal neurologic deﬁcit (both minor
and major stroke) lasting for more than 24 hours. An AMI
was deﬁned as a rise and/or fall of cardiac biomarker values
(troponin I) with at least one value above the reference
limit and with at least one of the following: symptoms of
ischemia: new or presumed new, signiﬁcant ST segment T-
wave changes or new left bundle branch block; develop-
ment of pathological Q waves in the ECG; imaging evidence
of new loss of viable myocardium; identiﬁcation of an
intracoronary thrombus by angiography or autopsy.
Statistical analyses
According to a previous Swedvasc study on CEA patients14
all patients were categorized into different groups
depending on the interval between qualifying event and
intervention: 0e2 days, 3e7 days, 8e14 days, and 15e180
days. For comparison with other publications25,26,32 of ur-
gent treatment for carotid artery stenosis, a secondary
analysis was also performed with an alternative categori-
zation: 0e7 days, 8e14 days, 15e28 days, and 29e180
days. Because of limited power we also compared 0e7 days
versus 8e180. The primary outcome was the 30 day com-
bined stroke and death rate. The secondary outcome was
the 30 day combined stroke, AMI, and death rate.
508 M. Jonsson et al.Continuous data are presented with mean and standard
deviation (SD) and median and interquartile range (IQR)
whenever applicable. The Fisher exact test was used for
categorical data whenever possible (if not, chi-square) and a
t test was used for continuous data; all tests were two sided
and statistical signiﬁcance was deﬁned as p < .05. Conﬁ-
dence intervals for proportions were calculated with the
modiﬁed Wald method (Graphpad.com). All other data
were analyzed using IBM SPSS statistics version 22.Table 1. Baseline characteristics in relation to time to CAS for 323 pat
Time to CAS, day
0e2
Patients, n 13
Male sex, n (%) 10 (76.9)
Age, yrs (SD) 69 (6.4)
Octogenarians, n (%) 2 (15.4)
Current smokers (N ¼ 257), n (%) 2 (16.7)
Comorbidities, n (%)
Cardiac disease (N ¼ 265) 4 (30.8)
Pulmonary disease (N ¼ 259) 3 (23.1)
Diabetes mellitus (N ¼ 304) 5 (38.5)
Hypertension (N ¼ 303) 10 (76.9)
Renal insufﬁciency (N ¼ 314) 2 (16.7)
Neurologic event, n (%)
Amaurosis fugax 2 (15.4)
TIA 2 (15.4)
Minor stroke 8 (61.5)
Crescendo TIA 0 (0.0)
Major stroke 1 (7.7)
Ipsilateral stenosisb
<50% 1 (7.7)
50e69% 2 (15.4)
70% 9 (69.2)
Contralateral stenosis (N ¼ 316)b
<50% 9 (75.0)
50e69% 0 (0.0)
70% 1 (8.3)
Occlusion 2 (16.7)
Indication for endovascular approach
RCT 1 (7.7)
Restenosis 0 (0.0)
Previous neck radiation or neck surgery 1 (7.7)
Comorbidity 2 (15.4)
Surgical inaccessible stenosis 3 (23.1)
Patients choice 0 (0.0)
Not speciﬁed reason 6 (46.2)
Protection device (N ¼ 322), n (%)
None 2 (15.4)
Occlusion balloon 0 (0.0)
Filter 9 (69.2)
Reversed Flow 2 (15.4)
Postop medication
Statins (N ¼ 303), n (%) 11 (84.6)
Antiplatelet therapy (N ¼ 311)
Single antiplatelet n (%) 2 (15.0)
Dual antiplatelet n (%) 10 (76.9)
Anticoagulation, n (%) 1 (7.7)
CAS ¼ carotid artery stenting; TIA ¼ transient ischemic attack.
a p-Values were calculated by chi-square and t tests.
b Degree of stenosis according to the NASCET criteria.RESULTS
Patient characteristics
In total, 323 patients (average age 71 years, 70% men)
underwent CAS for symptomatic carotid stenosis between
January 1, 2005, and March 20, 2014: 138 with TIA (42.7%),
118 minor stroke (36.5%), 61 amaurosis fugax (18.9%), ﬁve
major stroke (1.5%), and one crescendo TIA (0.3%) (Table 1).
Intervention was performed a median 13 days after theients.
s
3e7 8e14 15e180 p
85 80 145
58 (68.2) 60 (74.1) 98 (67.6) 0.620
71 (8.7) 72 (9.3) 70 (8.7) 0.306a
14 (16.5) 17 (21.3) 24 (16.6) 0.811
19 (30.6) 19 (31.1) 27 (22.0) 0.350
32 (37.6) 29 (35.8) 64 (44.1) 0.321
9 (10.6) 11 (13.6) 15 (10.3) 0.597
21 (24.7) 21 (25.9) 35 (24,1) 0.880
62 (73.8) 61 (75.3) 108 (75,0) 0.939
5 (6.0) 5 (6.4) 7 (5.0) 0.445
15 (17.6) 9 (11.1) 35 (24.1) 0.119
37 (43.5) 37 (46.3) 62 (42.8) 0.221
30 (35.3) 32 (39.5) 48 (33.1) 0.194
0 (0.0) 1 (1.3) 0 (0.0) 0.384
3 (3.5) 2 (2.5) 0 (0.0) 0.052
0.110
4 (4.7) 4 (4.7) 4 (2.8)
25 (29.4) 27 (33.8) 46 (31.7)
56 (65.9) 49 (61.3) 94 (64.8)
0.961
57 (67.9) 55 (68.8) 92 (65.7)
12 (14.3) 9 (11.3) 20 (14.3)
8 (9.5) 8 (10.0) 13 (9.3)
7 (8.3) 8 (10.0) 15 (10.7)
0.154
10 (11.8) 10 (12.5) 18 (12.4)
2 (2.4) 3 (3.8) 18 (12.4)
9 (10.6) 13 (16.3) 22 (15.2)
28 (32.9) 22 (27.5) 36 (24.8)
13 (15.3) 14 (17.5) 16 (11.0)
3 (3.5) 3 (3.8) 9 (6.2)
20 (23.5) 15 (18.8) 25 (17.2)
0.047
9 (10.6) 9 (11.3) 10 (6.9)
5 (5.9) 6 (7.5) 7 (4.8)
38 (44.7) 37 (46.3) 99 (68.3)
32 (37.6) 26 (32.5) 26 (17.9)
72 (84.7) 64 (80.0) 122 (84.1) 0.885
0.603
5 (5.9) 3 (3.8) 15 (10.3)
71 (83.5) 67 (83.8) 108 (74.5)
7 (8.2) 4 (5.0) 6 (4.1)
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endovascular approach rather than CEA are speciﬁed in
Table 1. Protection devices were used in 90.6% of the pa-
tients. Several different protection devices were used as
listed in Table 1: a ﬁlter was most frequently used (58%),
followed by reversed ﬂow (Neuro Protection System, WL
Gore, Flagstaff, AZ, USA).
Post-operatively, 82.3% were prescribed dual antiplatelet
therapy for at least 1 month, 9.6% anticoagulation therapy,
and 89.0% were prescribed statins.
The numbers of patients in the respective time groups
were 13 patients 0e2 days; 85 patients 3e7 days; 80 pa-
tients 8e14 days; and 145 patients 15e180 days. For the
secondary analyses the respective numbers were 98 pa-
tients 0e7 days; 80 patients 8e14 days; 62 patients 15e28
days, and 83 patients 29e180 days.
There were no statistically signiﬁcant differences be-
tween the groups with respect to background data,
comorbidities, and ipsi- or contralateral grade of stenosis
(Table 1). Major stroke as the reason for attending a health
care center was slightly more common in the group treated
within 2 days than the other groups (7.7% vs. 3.5%, 2.5%
and 0.0% respectively, p ¼ .052).
For the secondary analyses there were no signiﬁcant
differences between the different time groups with respect
to comorbidities and background data.Procedure related adverse events
Major peri-operative complications (stroke/death/AMI)
occurred in 21 of the 323 patients (6.5%). The thirty day
stroke and death rate for the whole group was 4.6%, and the
stroke rate was 4.0%. Four (1.2%) died within 30 days from
the procedure and seven (2.2%) had a myocardial infarction.
Rates of peri-operative complications based on time from
onset of symptoms to intervention are shown in Table 2. In
the group treated within 2 days of the qualifying event, no
patients (0 of 13 patients) suffered from procedure related
stroke or death. However, the 30 day combined stroke and
death rate did not differ signiﬁcantly between the groups:
zero of 13 (0%; 95% CI 0e26.6) in the group treated 0e2
days versus four of 85 (4.7%; 95% CI 1.5e11.9) at 3e7 days,
ﬁve of80 (6.3%; 95% CI 2.4e14.1) at 8e14 days, and six of
145 (4.1%; 95% CI 1.7e8.9) for the patients treated at 15e
180 days (p ¼ .757).Table 2. Procedural adverse events.
Time to CAS (days)
0e2 (n ¼ 13) 3e7 (n ¼
Stroke, n (%) 0 (0.0) 3 (3.5)
AMI, n (%) 0 (0.0) 3 (3.5)
Deaths, n (%) 0 (0.0) 0 (0.0)
Stroke/death, n (%)
(95% CI)
0 (0.0)
(0e26.6)
4 (4.7)
(1.5e11.
Stroke/death/AMI, n (%) (95%CI) 0 (0.0)
(0e26.6)
7 (8.2)
(3.8e16.
AMI ¼ acute myocardial infarction; CAS ¼ carotid artery stenting; CI
p-Values were calculated by the chi-square test.Stroke and death were not more frequent for patients
treated within 1 week of the onset of the qualifying event
than after 1 week: four of 98 (4.1%; 95% CI 1.3e9.0) versus
11 of 225 (4.9%; 95% CI 2.7e8.6) (p ¼ .751).
The secondary endpoint, 30 day combined stroke, death,
and AMI, was also none (0 of 13) in the group treated
within 2 days versus seven of 85 (8.2%; 3.8e16.3), six of 80
(7.5%; 3.2e15.7), and eight of 145 (5.5%; 2.7e10.7) for the
patients treated at 3e7 days, 8e14 days, and 15e180 days
respectively (p ¼ .640).
In the secondary analysis, with four different time periods
the combined stroke and death rate were similar for all
subgroups: 4.1% (1.3e9.0) for the group treated in 0e7
days versus 6.3% (2.4e14.2) treated in 8e14 days, 4.8%
(1.1e13.8) in 15e28 days, and 3.6% (0.1e10.5) in 29e180
days (Table 3).
Time trends
In the ﬁrst half of the study period (January 2005 to August
2009), 4.9% of the symptomatic carotid stenoses in Sweden
were treated by CAS (n ¼ 187), and the median interval
from the qualifying event to intervention was 15 days. The
30 day stroke and death rate during this period was 4.9%. In
the second time period (August 2009 to March 2014), the
rate of patients treated by CAS had decreased to 3.4%
(n ¼ 136). The median time to intervention had decreased
from 15 to 10 days. The 30 day stroke and death rate during
this study period was 5.9%. In the ﬁrst half of the study
period, nine centers performed CAS, seven of them
continued in the second time period.
DISCUSSION
In this nationwide study, no signiﬁcant differences between
patients that underwent CAS within 2 days or within 1 week
compared with those with delayed intervention were
observed. In addition, there was no trend towards an
increased risk with an early CAS procedure either with the
primary (stroke/death) or secondary endpoint (stroke/
death/AMI). On the contrary, no peri-procedural complica-
tion or death was observed among those treated within the
ﬁrst 2 days of the onset of symptoms.
There are limited previous data regarding CAS in the early
phase after a neurological event. The CAPTURE registry, a
retrospective cohort study with a total of 482 symptomatic85) 8e14 (n ¼ 80) 15e180 (n ¼ 145) p
5 (6.3) 5 (3.5) 0.626
2 (2.5) 2 (1.4) 0.602
3 (3.8) 1 (0.7) 0.126
9)
5 (6.3)
(2.4e14.1)
6 (4.1)
(1.7e8.9)
0.757
3)
6 (7.5)
(3.2e15.7)
8 (5.5)
(2.7e10.7)
0.640
¼ conﬁdence interval.
Table 3. Procedural adverse events (secondary time classiﬁcation).
Time to CAS (days)
0e7 (n ¼ 98) 8e14 (n ¼ 80) 15e28 (n ¼ 62) 29e180 (n ¼ 83) p
Stroke, n (%) 3 (3.1) 5 (6.3) 2 (3.2) 3 (3.6) 0.706
AMI, n (%) 3 (3.1) 2 (2.5) 1 (1.6) 1 (1.2) 0.688
Deaths, n (%) 0 (0.0) 3 (3.8) 1 (1.6) 0 (0.0) 0.091
Stroke/death, n (%)
(95%CI)
4 (4.1)
(1.3e9.0)
5 (6.3)
(2.4e14.2)
3 (4.8)
(1.1e13.8)
3 (3.6)
(0.1e10.5)
0.864
Stroke/Death/AMI, n (%)
(95% CI)
7 (7.1)
(3.3e14.3)
6 (7.5)
(3.2e15.7)
4 (6.5)
(2.1e15.9)
4 (4.8)
(1.5e12.1)
0.900
AMI ¼ acute myocardial infarction; CAS ¼ carotid artery stenting; CI ¼ conﬁdence interval.
p-Values were calculated by the chi-square test.
510 M. Jonsson et al.patients treated with CAS found an increased stroke and
death rate when CAS was performed in the ﬁrst 2 weeks of
onset of neurologic symptoms compared with other
symptomatic patients.30 A few small single center series
have published results that indicate it is safe to perform CAS
acutely; Setacci et al.26 presented results from 26 patients
with TIA that were treated with CAS within 48 hours with a
stroke/death rate of 3.8%. Wach et al.25 published results
from their institution in 2013; 221 patients were analyzed in
total. Patients treated urgently (0e2 days) or early (3e7
days) did not have inferior results compared with those
treated later. These results are thus consistent with the
present study, and are summarized in Table 4.
In a pooled analysis from patients randomized in the
ICSS, EVA-3S and SPACE studies, Rantner et al.28 found that
patients treated with CAS within 7 days had a stroke or
death rate of 9.4%, compared with 8.1% if treated after 8e
14 days and 7.3% when treated after more than 2 weeks
from the qualifying event.
For CEA there are data on the risks of early compared with
later interventions. A recent meta-analyses and a large cohort
study could not ﬁnd a higher peri-operative stroke and death
rate if the patients underwent CEA in the subacute phase.32,33
Several small series have published CEA results in the acute
phase that are the same as delayed surgery,16e18,34e36 and,
just recently, a retrospective analysis from Rantner et al.37
could not detect any signiﬁcant differences between pa-
tients undergoing CEA in the within 2 days compared with
delayed operation. On the contrary, a recently published study
from Sweden demonstrated a very high incidence of peri-Table 4. Studies analyzing stroke or death after CAS in relation to tim
Time to CAS (days)
0e2 3e7
Wach et al. 201325 7.1% (5/70) 4.5% (4/
Rantner et al. 201328 9.4%a (13
Topakian et al. 200729
Gröschel et al. 200827
Setacci et al.26,e 3.8% (1/26)
a 0e7 days.
b 0e14 days.
c 0e13 days.
d 14e180 days.
e Only patients with transient ischemic attack included.operative complications for patients operated on by CEA
within 48 hours.14 It has been debated, however, if a possible
high complication rate could be justiﬁed when compared with
the signiﬁcant risk of stroke on medical treatment alone, if
surgery is delayed.38,39 The early risk of recurrent stroke with
only medical treatment is also high in patients with recently
symptomatic carotid stenosis.1e9
The strength of this study is that it is a large population
based study investigating the risks of urgent CAS. It has
national coverage and reﬂects the clinical reality in a small
country. Data quality on outcomes is good with few
missing values. In the study the median delay was 13 days
from symptom to stenting. More than half (56%) were
treated within 2 weeks of symptoms. This could be
compared with the pooled results from the randomized
trials by Rantner et al.,28 where 36% were stented within
2 weeks and the median delay was 29 days. Also, in that
analysis there were missing data on the delay for 15% of
stented patients.
However, small numbers limit this report, especially since
few patients underwent CAS within 2 days of the onset of
symptoms. A type II error when looking at only those
stented within 48 hours cannot be excluded. The risk of
stroke and death resulting from CAS is relatively low, and
very large sample sizes are often required to reduce conﬁ-
dence intervals. The selected material limits the generaliz-
ability of the study. The indications for the endovascular
approach in Table 1 show that many of these patients
would have been suboptimal for open surgery and might
have an increased overall risk.ing.
8e14 15e180
88) 2.8% (1/36) 0% (0/27)
/138) 8.1% (19/234) 7.3% (78/1062)
26%b (6/23) 1.9% (1/54)
7.0%c (10/142) 10.0%d (17/178)
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In this national registry study, CAS performed within 1 week
of the onset of a neurological event was not associated with
additional risk of suffering a peri-operative complication
compared with those treated subsequently.
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